SuperworthIDEXX Laboratories IDXX
- Market cap
- $44.1B
- PE
- 39.4×
- 10y median 55.0×
- Forward PE
- 35.9×
- 10y median 50.3×
- Price to sales
- 9.7×
- EV/EBIT
- 30.3×
- Revenue, 12 months
- $4.6B
- +13% on a year ago
- Net margin
- 25.0%
- Free cash flow yield
- 2.8%
IDEXX Laboratories trades at 39.4× trailing earnings, cheaper than 97% of the last ten years. Revenue was $4.6B over the last twelve months, up 13% on a year earlier with a 25% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $915.5M+9% | $901.6M+9% | $964.1M+7% | $1B+6% | $975.5M+7% | $954.3M+6% | $998.4M+4% | $1.1B+11% | $1.1B+13% | $1.1B+14% | $1.1B+14% | $1.2B+10% | |
| Cost of revenue | $367.5M+10% | $375.4M+9% | $371M+4% | $384.4M+4% | $379.5M+3% | $383.6M+2% | $375M+1% | $414.7M+8% | $421.9M+11% | $432.5M+13% | $418.1M+12% | $437.5M+6% |
| Gross profit | $548M+8% | $526.2M+9% | $593.1M+9% | $619.2M+8% | $596M+9% | $570.7M+9% | $623.4M+5% | $694.7M+12% | $683.4M+15% | $658.1M+15% | $722.7M+16% | $779.1M+12% |
| R&D | $48M−0% | $51.8M+19% | $52.6M+18% | $55.5M+19% | $54M+13% | $57.7M+11% | $59.1M+12% | $61.9M+12% | $63.4M+18% | $66.8M+16% | $65.8M+11% | $65.4M+6% |
| SG&A | $224.7M+5% | $229.1M+7% | $241.5M+11% | $299.9M+30% | $238.2M+6% | $251.2M+10% | $247.8M+3% | $259.8M−13% | $265.1M+11% | $275.7M+10% | $294.4M+19% | $288.1M+11% |
| $275.3M+12% | $245.3M+8% | $299M+7% | $263.8M−11% | $303.9M+10% | $261.7M+7% | $316.5M+6% | $373M+41% | $354.8M+17% | $315.6M+21% | $362.6M+15% | $425.6M+14% | |
| Interest expense | $8.6M−21% | $9.3M−32% | $7.9M−40% | $8.1M−23% | $7.7M−11% | $7.5M−19% | $7.7M−3% | $11.3M+40% | $10.7M+38% | $9.2M+23% | $7.7M+1% | $10.2M−10% |
| Pre-tax income | $267.9M+14% | $239.7M+12% | $295.5M+10% | $259.1M−9% | $298.9M+12% | $256.4M+7% | $310.1M+5% | $362.4M+40% | $344.8M+15% | $307M+20% | $355.4M+15% | $417.2M+15% |
| $55.7M+5% | $45.1M+10% | $59.9M+12% | $55.8M−10% | $66.1M+19% | $40.2M−11% | $67.4M+13% | $68.4M+23% | $70.2M+6% | $58.8M+46% | $77M+14% | $78.8M+15% | |
| Net income | $212.2M+17% | $194.5M+13% | $235.6M+10% | $203.3M−9% | $232.8M+10% | $216.1M+11% | $242.7M+3% | $294M+45% | $274.6M+18% | $248.2M+15% | $278.4M+15% | $338.4M+15% |
| $2.53+18% | $2.32+13% | $2.81+10% | $2.44−9% | $2.80+11% | $2.62+13% | $2.96+5% | $3.63+49% | $3.40+21% | $3.08+18% | $3.47+17% | $4.27+18% | |
| 84M−0% | 83.9M+0% | 84M+0% | 83.4M−1% | 83.1M−1% | 82.6M−2% | 81.9M−2% | 81M−3% | 80.7M−3% | 80.5M−3% | 80.2M−2% | 79.3M−2% |
EPS, diluted: 10 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 17 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $1.2B | $1.2B to $1.2B | $3.72 | $3.65 to $3.77 | 8 |
| Q4 FY26 | $1.2B | $1.2B to $1.2B | $3.39 | $3.36 to $3.42 | 8 |
| Q1 FY27 | $1.2B | $1.2B to $1.2B | $3.89 | $3.87 to $3.94 | 3 |
| Q2 FY27 | $1.3B | $1.3B to $1.3B | $4.64 | $4.61 to $4.69 | 4 |
| Q3 FY27 | $1.3B | $1.3B to $1.3B | $4.26 | $4.24 to $4.31 | 3 |
| Q4 FY27 | $1.3B | $1.3B to $1.3B | $3.89 | $3.87 to $3.93 | 4 |
| Q1 FY28 | $1.3B | $1.3B to $1.3B | $4.28 | $4.26 to $4.33 | 4 |
| Q2 FY28 | $1.4B | $1.4B to $1.4B | $5.29 | $5.27 to $5.35 | 5 |
Peers
Companies in Medical - Diagnostics & Research nearest IDEXX Laboratories' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| IQVIQVIA | $46B | 34.7× | 34.9× | 20.5× | 2.7× | +8% | 8.1% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| AAgilent Technologies | $48.8B | 34.0× | 33.1× | 26.4× | 6.6× | +9% | 19.5% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| DHRDanaher | $162B | 40.9× | 34.2× | 25.4× | 6.5× | +5% | 15.9% |
| Peer median | $37.1B | 38.4× | 34.3× | 26.4× | 6.5× | +8% | 12.6% |
Investors who own it
Investors we follow who held IDEXX Laboratories at the end of Jun 30, 2026, from their 13F filings.
- Terry SmithFundsmith3.9% of portfoliotrimmed
- Polen CapitalPolen Capital2.4% of portfoliotrimmed
- Ron BaronBaron Capital1.6% of portfolioadded
- Baillie GiffordBaillie Gifford0.2% of portfolionew
- Bill NygrenHarris Associates (Oakmark)0.0% of portfoliotrimmed
More on IDEXX Laboratories
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 39Diagnostics and research stocks with the highest profit margins
- #3of 92Healthcare stocks cheapest against their own PE history
- #1of 15Diagnostics and research stocks cheapest against their own PE history
- #6of 17Diagnostics and research stocks with the fastest earnings growth
- #5of 11Diagnostics and research stocks with the fastest expected revenue growth
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .